IDEXX Laboratories, Inc. $IDXX Shares Sold by Rathbones Group PLC

Rathbones Group PLC cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 117,569 shares of the company’s stock after selling 19,650 shares during the period. Rathbones Group PLC owned approximately 0.15% of IDEXX Laboratories worth $75,114,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Empowered Funds LLC raised its stake in shares of IDEXX Laboratories by 6.6% during the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after buying an additional 95 shares during the period. Sivia Capital Partners LLC acquired a new position in IDEXX Laboratories during the second quarter worth $265,000. Moors & Cabot Inc. purchased a new position in IDEXX Laboratories during the second quarter valued at $228,000. Resona Asset Management Co. Ltd. grew its position in shares of IDEXX Laboratories by 4.7% in the second quarter. Resona Asset Management Co. Ltd. now owns 28,079 shares of the company’s stock valued at $15,038,000 after purchasing an additional 1,255 shares during the period. Finally, Achmea Investment Management B.V. increased its stake in shares of IDEXX Laboratories by 100.1% during the second quarter. Achmea Investment Management B.V. now owns 4,232 shares of the company’s stock worth $2,270,000 after purchasing an additional 2,117 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the sale, the director owned 648 shares in the company, valued at $407,345.76. The trade was a 69.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the company’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total value of $15,338,011.30. Following the completion of the transaction, the chief executive officer directly owned 83,606 shares in the company, valued at approximately $54,975,125.30. This trade represents a 21.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 45,957 shares of company stock valued at $29,862,109 over the last 90 days. Corporate insiders own 0.98% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several research analyst reports. Barclays reduced their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Piper Sandler cut their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. BTIG Research decreased their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Finally, UBS Group lowered their price target on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $608.41 on Friday. The company’s 50-day moving average is $666.94 and its two-hundred day moving average is $668.42. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The firm has a market capitalization of $48.44 billion, a price-to-earnings ratio of 46.55, a PEG ratio of 3.70 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.